% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Merz:128100,
author = {M. Merz and A. Jauch and T. Hielscher$^*$ and E. K. Mai and
A. Seckinger and D. Hose and U. Bertsch and K. Neben and
M.-S. Raab$^*$ and H. Salwender and I. W. Blau and H.-W.
Lindemann and I. Schmidt-Wolf and C. Scheid and M. Haenel
and K. Weisel and H. Goldschmidt and J. Hillengass$^*$},
title = {{L}ongitudinal fluorescence in situ hybridization reveals
cytogenetic evolution in myeloma relapsing after autologous
transplantation.},
journal = {Haematologica},
volume = {102},
number = {8},
issn = {1592-8721},
address = {Pavia},
publisher = {Ferrata Storti Foundation},
reportid = {DKFZ-2017-04122},
pages = {1432 - 1438},
year = {2017},
abstract = {To investigate cytogenetic evolution after upfront
autologous stem cell transplantation for newly diagnosed
myeloma we retrospectively analyzed fluorescence in situ
hybridization results of 128 patients with paired bone
marrow samples from the time of primary diagnosis and at
relapse. High-risk cytogenetic abnormalities (deletion 17p
and/or gain 1q21) occurred more frequently after relapse
(odds ratio: 6.33; $95\%$ confidence interval: 1.86-33.42;
P<0.001). No significant changes were observed for defined
IGH translocations [t(4;14); t(11;14); t(14;16)] or
hyperdiploid karyotypes between primary diagnosis and
relapse. IGH translocations with unknown partners occurred
more frequently at relapse. New deletion 17p and/or gain
1q21 were associated with cytogenetic heterogeneity, since
some de novo lesions with different copy numbers were
present only in subclones. No distinct baseline
characteristics were associated with the occurrence of new
high-risk cytogenetic abnormalities after progression.
Patients who relapsed after novel agent-based induction
therapy had an increased risk of developing high-risk
aberrations (odds ratio 10.82; $95\%$ confidence interval:
1.65-127.66; P=0.03) compared to those who were treated with
conventional chemotherapy. Survival analysis revealed dismal
outcomes regardless of whether high-risk aberrations were
present at baseline (hazard ratio, 3.53; $95\%$ confidence
interval: 1.53-8.14; P=0.003) or developed at relapse only
(hazard ratio, 3.06; $95\%$ confidence interval: 1.09-8.59;
P=0.03). Our results demonstrate cytogenetic evolution
towards high-risk disease after autologous transplantation
and underline the importance of repeated genetic testing in
relapsed myeloma (EudraCT number of the HD4 trial:
2004-000944-26).},
cin = {C060 / G170 / E010},
ddc = {610},
cid = {I:(DE-He78)C060-20160331 / I:(DE-He78)G170-20160331 /
I:(DE-He78)E010-20160331},
pnm = {315 - Imaging and radiooncology (POF3-315)},
pid = {G:(DE-HGF)POF3-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28495913},
pmc = {pmc:PMC5541876},
doi = {10.3324/haematol.2017.168005},
url = {https://inrepo02.dkfz.de/record/128100},
}